Oleoylethanolamide (OEA) (111-58-0)

March 11, 2020
SKU: 16589-24-5
5.00 i waho o 5 ma muli o 1 Customer pane lākiō

ʻO Oleoylethanolamide (OEA) kahi agogist progiferator peroxisome-activated alpha (PPAR-alpha) agonist. He He …… ..


Kūlana: I ka Production Production
Mokuna: 25kg / Drum

Oleoylethanolamide (OEA) (111-58-0) wikiō

Oleoylethanolamide (OEA) (111-58-0) Nā kuʻina

Product Name ʻO ka pauma Oleoylethanolamide (OEA)
Hawaiian Name n-oleoylethanolamine; N- (2-Hydroxyethyl) oleamide; Oleylethanolamide;

N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide;

Oleoyl Ethanolamide;

Kāleka CAS 111-58-0
InChIKey BOWVQLFMWHZBEF-KTKRTIGZSA-N
SMILE CCCCCCCCC = CCCCCCCCC (= O) NCCO
Ka Lā Molecular C20H39NO2
Molecular Weight 325.5 g / mole
Monoisotopic Mass 325.537 g · mol-1
Point Hoʻolālā 59-60 ° C (138 – 140 ° F; 332-333 K)
ʻO Boiling Point 496.4 ± 38.0 ° C (Manaʻo ʻia)
nuʻa 0.915 ± 0.06 g / cm3 (Puhi ʻia)
kala like 'ole ʻO ka pauma
Shoʻoweliweli temp -20 ° C
Mālama i ka ethanol a me DMSO Hoʻololiʻia
noi Palapala phamaceutical; hoʻouka;

Overview

ʻO Oleoylethanolamide (OEA) a i ʻole N-Oleoylethanolamide (OEA) he molekamu i hua ʻia i loko o ke kino, ka mea maʻamau i ʻike ʻia i loko o nā ʻāpana. Ke hōʻike nei ka hoʻonui ʻana i nā hōʻike e hiki ai ke hana ʻoEA me he mea endogenous neuroprotective ma ke komo ʻana i ka kaohi o nā ʻano hana. Eia kekahi, ua hōʻike ʻia kahi mea hoʻohana peripherally e hōʻemi ana i ka meaʻai a me ka loaʻa ʻana o ke kaumaha.

He aha ka Oleoylethanolamide (OEA)?

ʻO Oleoylethanolamide (OEA) kahi agogist progiferator peroxisome-activated alpha (PPAR-alpha) agonist. ʻO ia he kūlohelohe glycolamide lipid me ka ʻano o nā ʻano homeostasis kūʻokoʻa e like me ka makemake o ka makemake, ka hana anti-inflammatory, ka hoʻoulu ʻana i ka lipolysis me ka momona o ka hoʻōho momona. Hiki ke manaʻo ʻia ʻo Oleoylethanolamide he hormone o ke aʻa o ka ʻōpū o ka ʻōpū. ʻO ka oatmeal, nā nati, a me ka pauku koko ka puna nui nā kumu o Oleoylethanolamide i nā meaʻai. Akā, ʻo ka nui o Oleoylethanolamide i loaʻa i kēia mau meaʻai he haʻahaʻa (ʻoi aku ma mua o 2 µg / g).

Ma ke ʻano he lipid active biidically olidlethanolamide (OEA) i loko o ka ʻōpū a me nā ʻano ʻili, a ua kau ʻia i nā hoʻoponopono kōpaʻa o ka ikehu o ka molmalian, hoʻoponopono i ka lawelawe o ka meaʻai a me ka molake molid, e like me ia ka mea e hoʻoponopono i ka meaʻai ʻo Vertebrate a me ke kaumaha o ke kino. ʻO Oleoylethanolamide kahi fatty acid ethanolamide (FAE), kahi monounsaturated analog o endocannabinoid arachidonic acid ethanolamide (anandamide), a me kahi hana anagonide hoʻoikaika. He mea pono ia e ʻokoʻa i ka mana o Oleoylethanolamide mai anandamide, kūʻokoʻa ia i ka mea hoʻokipa cannabinoid, a hana i kāna hana bioloola ma o nā ala ʻē aʻe, e hoʻoponopono ana i ka hana PPAR-α e hoʻoulu ai i ka lipolysis. ʻO Oleoylethanolamide kahi kūpono a palekana palekana anti-obesity i mea e hoʻohuli ai i ka antagonism CB1.

Ua hōʻike ʻia nā haʻawina preclinical ʻo Oleoylethanolamide kahi maikaʻi anti-inflammatory a me ka antioxidant pūlea e hōʻeuʻeu aku i nā hopena neuroprotective ma ka ʻalā. Hiki i ka hoʻokele Exogenous o Oleoylethanolamide hiki ke pale aku i ka hōʻino o ka wai lālau ʻana o ka TLR4-mediated citrex aine o ka wai, a laila hoʻēmi i ka hoʻokuʻu ʻana o nā cytokine proinflamerian a me ka chemokines, oxidative a me ka nitrosative stress, a hiki i ka pale mua i ka hoʻopilikia kino i ka cortex frontal o nā rodents.

Nā kumuwaiwai o Oleoylethanolamide (OEA)

ʻElua mau kumu o ka loaʻa ʻana o Oleoylethanolamide (OEA), hoʻokahi mai ka lāʻau kūlohelohe, a ʻo kahi ʻē aʻe ma ke ʻano ʻokoʻa ma ka ʻalani.

ʻO Achyranthes Aspera, ka mea hānau i India, Kina a me nā aupuni ʻē aʻe o ʻAmelika, i ʻōlelo ʻia he pū ia ʻo Oleoylethanolamide OEA. ʻO ka pilikia o Oleoylethanolamide maoli-sourced aia wale nō ka mea loaʻa wale ke kaulike, 15: 1 kahi hiʻona kaulana loa ia, ʻaʻole ia e like me ka mea e manaʻo ʻia ai nā mea kūʻai a ma nā mea hoʻohui a nā mea hana e manaʻo nei. ʻO kaʻoiaʻiʻo, hiki ke kiʻekiʻe loa, akā e kiʻekiʻe loa ke kumukūʻai, no laila, ʻaʻole ia he mea kūpono ʻole e hana i ka Oleoylethanolamide kūlohelohe OEA me ka nui.

ʻO ka kumu kumu nui o Oleoylethanolamide i hoʻokaʻawale ʻia mai ka oleic acid, i lawelawe ʻia ma mua o N-oleoyl-phosphatidylethanolamine, a laila ʻoka ʻia e N-acyl-phosphatidylethanolamine-selektif phospholipase D (PLD) e hoʻokuʻu i ka Oleoylethanolamide OEA.

ʻO Oleoylethanolamide kahi metabolite maoli o ka waika oleic. No laila, ʻo nā meaʻai containg oleic acid he kumu hoʻopono kūpono i ka OEA.

Pehea ka hana a Oleoylethanolamide (OEA) e hana?

I ka poʻe momona, hiki i ka OEA ke hoʻoponopono i ka homeostasis ikaika a me ka makemake nui ma o ka hoʻōla ʻana o nā mea ʻae like ʻole me ka proliferator proliferator-activated receptor-α (PPAR-α), G-protein-Coupled receptor 119 (GPR119) a me ka transient receptor potation cation channel subfamily V (TRPV1). ʻOiaʻiʻo, hoʻomohala ʻo OEA i kēia mau mea nānā aku a hoʻohemo i ka hoʻomaka ʻana o ka papaʻaina, e hōʻemi ana i ka nui o ka pāʻina, a hoʻoneʻe i nā kikowaena ma waena o ka papaʻaina a no ka hoʻololi ʻana i ke kaumaha kino.

A, kekahi mau hoʻokolohua hoʻokolohua hōʻike ʻia e paʻa ana ka OEA i ka hōʻike o IL-6, interleukin-8 (IL-8), molekui interhesular molina-1 (ICAM-1) a me ka molopole adhesion cell vascular-1 (VCAM-1) i ka TNF -a me ka hoʻowalewale i ke kani ʻana i nā pona endothelial i ka umbilical urina ma o ka hoʻōla ʻana o nā ʻili. Ua kāpili ʻo OEA i ke ala o ke ala neo kappa-B (NF-kB) i ke ala. Ma ka hōʻike ʻo YT et al, ua hoʻokuʻu aku ʻo OEA (50 µmol / L) i ka hōʻike o TNF-α i loaʻa ai ka hōʻike VCAM-1 ma HUVEC.

ʻO nā pono o Oleoylethanolamide (OEA)

ʻO ka pauka Oleoylethanolamide (OEA) maikaʻi ia e hōʻemi i ka paona e like me ka mea hoʻoponopono momona a kākoʻo i nā pae kūlohelohe olakino i nā pākeke.

Oleoylethanolamide (OEA) ma he mea he hana hoʻonoho pule

ʻO ke kūpaʻa ʻana i ka momona a no laila e hoʻemi ai i ka ʻai ʻana o ka meaʻai i ke ala maikaʻi i ke kāohi ʻana i ka kaulike o ka ikehu a me ke kaumaha o ke kino. No ka mea, he mālama koʻikoʻi ka mālama ʻana i ka momona (ka ʻai), ka mālama ʻana i ka makemake i ka nui o ka mālama ʻana i ke kaumaha o ke kino maikaʻi, ʻoi loa ka hui pū ʻana me nā koho ola olakino e pili ana ka mālama ʻana i ka meaʻai kūpono, hoʻohui i kaʻai, a me ka hana.

ʻO ka Oleoylethanolamide supplementation kōkua i ka hoʻoponopono ʻana i ka lipid metabolism, kōkua i ka mālama ʻana i ka pōloli ma ka hoʻouna ʻana i nā ʻelele surpressant i ka lolo a ua hōʻike ʻia e kōkua i nā pae triglyceride a me nā pae kolamu koko.

Oleoylethanolamide no ka hoʻokele momona ʻana o ke kino

ʻOEA he mīkini palekana palekana peripheral e pale ana i ka momona a me nā lilo o ka hiki.

Ua aʻo mua ʻia nā hopena o OEA no ka mea ke kaʻana like i nā mea like me kekahi kemika, kahi cannabinoid kaulana ʻo anandamide. ʻO ka Cannabinoids e pili ana i ka mea kanu Cannabis, a me nā anandamides i loaʻa i ka mea kanu (a me ka mariuana) hiki ke hoʻonui i ka makemake o kekahi kanaka i ka hana ma o ka hoʻonā ʻana i ka pane hānai. Wahi a Wikipedia, ʻo Oleoylethanolamide ka analoge monounsaturated o ka anandamide endocannabinoid. ʻOiai ʻo OEA he hale ulia e like me ka anandamide, ʻokoʻa nā hopena ma ka ʻai a me ka hoʻokele kaumaha. ʻAʻole i like anandamide, hana kūʻokoʻa ʻo OEA ma ke ala cannabinoid, ka hoʻoponopono ʻana i ka hana PPAR-α e hoʻoulu ai i ka lipolysis.

Hoʻolauna ka Oleoylethanolamide

Ua ʻimi nā poʻe a pau i ke olakino ma o ka bodybuilding i ka lepa. Ua ulu nui ka OEA i nā mea hoʻoikaika bodybuilders. Ma ke kīhāpai kai hoʻoulu kino, ʻo TTA (tetradecylthioacetic acid) pinepine a synergistically i hoʻohana ʻia me oleoylethanolamide (OEA), nā mea ʻelua e kōkua i ka puhi o ka momona a hoʻoemi i ka pōloli. Pēlā paha e hoʻolaha nui ʻia paha ʻo TTA ma waena o nā mea hoʻohui anti-momona, no ka mea, ʻo ia ka mea e hoʻopau i ka momona kūʻokoʻa o ka hoʻokō ʻana; Manaʻo nā hopena mua e ʻike wale ke kino e "wehe" i ka momona mai ia iho ma mua o ka pono e puhi ia i ka hana kino.

ʻO Oleoylethanolamide (OEA) e hōʻemi i ka triglycerides a me ka cholesterol, a, hui pū ʻia me ka antagonist cannabinoid, poloka i ka loaʻa ʻana o ka paona kino a hoʻomaikaʻi i ka dyslipidaemia i loko o nā hiʻohiʻona holoholona o ka momona.

Eia kekahi, ua loaʻa i ka lawelawe ʻōnaehana o oleoylethanolamide ke hoʻololi i ka homeostasis glucose, me ka hoʻokuʻu ʻia ʻana o ka insulin a me ka hōʻailona o ka insulin i nā hepatocytes a me nā adipocytes.

E hōʻike ana kekahi mau heleler e loaʻa i ka oleoylethanolamide supplemental he hopena kūpono i ka hopohopo, a he nui nā ala hou a me nā hōʻike e kākoʻo ai.

Pehea e hoʻohana ai iā Oleoylethanolamide OEA

Onā hopena hopena leoylethanolamide

ʻO Oleoylethanolamide OEA hou i ka mākeke hui, ʻaʻole i hōʻike ʻia nā hopena koʻikoʻi. ʻAʻohe pilikia o ka US Food and Drug Administration (FDA) e pili ana i ka palekana o OEA. I loko o ke ola o kēlā me kēia lā, ʻo oleoylethanolamide kahi mea e mālama ana i ka momona kaumaha, ka mea i hoʻohana ʻia e loiloi i ka nui o ka catabolism ma ka gastro-intestinal tract, e kōkua ana e hōʻemi i ka momona me ka ʻole o nā hopena laikake.

Oleoylethanolamide ʻike

ʻAʻohe mea e hāʻawi ʻia ai ka lehulehu no ka oleoylethanolamide ʻoiai nā mea hoʻohana oleoylethanolamide i loaʻa ʻole i ke kaulana a i kona wā mua. ʻO RiduZone ka pauma OEA mua i hōʻailona ʻia ma 2015.

ʻO ka dosle oleoylethanolamide i ʻōlelo ʻia ʻia ʻo ia i kapohima 200mg i ka wā i lawe ʻole ʻia ai

Ua noi ʻia e noiʻi hiki iā ʻoe ke hoʻohaʻahaʻa a hoʻonui i nā maʻi i kēlā me kēia lā e like me kou palaka.

100mg no kahi kanaka 150lb

145mg no kahi kanaka 200lb

180mg no kahi kanaka 250lb

Ke noi a Oleoylethanolamide (OEA)

Ua hoʻohana ka Oleoylethanolamide pauku i ka hoʻohui ʻana i ka olakino olakino, i hana ʻia i loko o ka capsule paʻakikī a papa paha no ka pohō kaumaha.

Reference:

  • Gaetani S, Oveisi F, Piomelli D (2003). "Ka lihalihi ʻana o ka pāʻina ʻai i ka iole e ka anorexic lipid mediator oleoylethanolamine". Neuropsychopharmacology. 28 (7): 1311–6. doi: 10.1038 / sj.npp.1300166. PMID 12700681.

  • Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D (2005). "Hoʻoponopono i ka ʻai ʻana ma ka oleoylethanolamine". Pūnaewele. Mol. Life Sci. 62 (6): 708–16. doi: 10.1007 / s00018-004-4494-0. PMID 15770421.

  • Giuseppe Astarita; Bryan C. Rourke; Johnnie B. Andersen; Jin Fu; Janet H. Kim; Albert F. Bennett; James W. Hicks & Daniele Piomelli (2005-12-22). "ʻO ka hoʻonui ʻana o ka hoʻihoʻi ole o ka oleoylethanolamine i loko o kahi pākahi liʻiliʻi o ka Python Burmese (Python molurus)". Am J Physiol Regul Integr Comp Physiol. 290 (5): R1407 – R1412. doi: 10.1152 / ajpregu.00664.2005. PMID 16373434.

  • Gaetani S, Kaye WH, Cuomo V, Piomelli D (September 2008). "Ka mana o ka endocannabinoids a me kā lākou analogues i ka lesity a me ka ʻai ʻana i ka maʻi." ʻAi Hoʻohui Paʻa. 13 (3): e42–8. PMID 19011363.

  • Serrano A, et al. Oleoylethanolamide: hopena i ka hoʻopili hypothalamic a me ka peptides o ke kao e hoʻoponopono ai i ka hoʻopono o ka meaʻai. Neuropharmacology. (2011)

NA HALO A E HOOLAHA:

E kūʻai ʻia ana kēia ʻano mea no ka noiʻi noiʻi wale nō. Wahi a ke kūʻai aku. ʻAʻole no ka loiloi kanaka, ʻaʻole lāʻau lapaʻau, manu hoʻāno, a i ʻole e kōkua ʻia nā mea hale.